FILTER

Refine your search with the following facets to narrow down your results.

3 Current news of tubulis

image description

Tubulis closes upsized €128 million Series B2

"This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space"

18-Mar-2024 - Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led byEQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life ...

antibody-drug conjugate cancer cancer therapeutics +2
image description

Tubulis Closes €60 Million Series B Financing

Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

05-May-2022 - Tubulis announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), ...

antibody-drug conjugate cancer Series B financing
image description

Tubulis Raises €10.7 M Series A

Further Development of a New Generation of Antibody-Drug Conjugates

22-Jul-2020 - Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tech ...

antibody-drug conjugate financing Series A financing